ALSAN ÇETİN, İ. Et Al. 2022. Prostate-specific antigen nadir within 1 year of radiotherapy combined with hormone therapy predicts cancer-specific mortality and biochemical recurrence-free survival in prostate cancer patients. BMC Urology , vol.22, no.1 .

ALSAN ÇETİN, İ., Akay, S. U., & Sengoz, M., (2022). Prostate-specific antigen nadir within 1 year of radiotherapy combined with hormone therapy predicts cancer-specific mortality and biochemical recurrence-free survival in prostate cancer patients. BMC Urology , vol.22, no.1.

ALSAN ÇETİN, İLKNUR, Sıtkı Utku Akay, And KAZIM MERİÇ ŞENGÖZ. "Prostate-specific antigen nadir within 1 year of radiotherapy combined with hormone therapy predicts cancer-specific mortality and biochemical recurrence-free survival in prostate cancer patients," BMC Urology , vol.22, no.1, 2022

ALSAN ÇETİN, İLKNUR A. Et Al. "Prostate-specific antigen nadir within 1 year of radiotherapy combined with hormone therapy predicts cancer-specific mortality and biochemical recurrence-free survival in prostate cancer patients." BMC Urology , vol.22, no.1, 2022

ALSAN ÇETİN, İ. Akay, S. U. And Sengoz, M. (2022) . "Prostate-specific antigen nadir within 1 year of radiotherapy combined with hormone therapy predicts cancer-specific mortality and biochemical recurrence-free survival in prostate cancer patients." BMC Urology , vol.22, no.1.

@article{article, author={İLKNUR ALSAN ÇETİN Et Al. }, title={Prostate-specific antigen nadir within 1 year of radiotherapy combined with hormone therapy predicts cancer-specific mortality and biochemical recurrence-free survival in prostate cancer patients}, journal={BMC Urology}, year=2022}